OvaScience Reports Third Quarter 2016 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new female infertility treatments, today reported its third quarter 2016 financial results and highlighted recent accomplishments.

“OvaScience is focused on laying the clinical and operational foundation necessary to support the successful launch of AUGMENT in key international regions,” said Harald Stock, Ph.D., President and Chief Executive Officer of OvaScience.

Back to news